Molecular Characteristics of Duchenne Muscular Dystrophy in a Lebanese Cohort
El-Khoury R¹, Ahdab-Barmada M¹, Souaid M² and Farra C*¹
¹Department of Pathology and Laboratory Medicine, Neuromuscular Diagnostic Laboratory, American University of Beirut Medical Center, Beirut, Lebanon
²Department of Pathology and Laboratory Medicine, Medical Genetics Unit, American University of Beirut Medical Center, Beirut, Lebanon

Abstract

**Background:** Duchenne Muscular Dystrophy (DMD) is a progressive neuromuscular disorder characterized by a relentless clinical course with diagnosis usually established around three to four years of age. DMD is caused by mutations in the dystrophin gene, where deletions and duplications of one or more exons represent the bulk of related genetic aberrations.

**Aims and methods:** Our aim in the current study is to analyze the frequency and the distribution pattern of deletions/duplications associated with dystrophin gene exons and assess the mean diagnostic age of DMD in a small Lebanese group of dystrophic patients suspected with DMD/BMD based on observed clinical features.

**Results and discussion:** Among 52 samples analyzed, we identified 33 cases (63%) with deletions and two cases (4%) with duplications. Deletions were of variable sizes, ranging from 1 to 47 exons and occurred mostly (78%) in two deletion hotspots (HS), HS1 (18%) and HS2 (60%), covering exons 6–19 and 45–52 respectively. Single exon deletions were even further restricted (90%) to the deletion hotspots, mainly to HS2 (80%). The average age of DMD molecular diagnosis in our subject study was 7 years of age.

**Conclusion:** Molecular analyses were consistent with those obtained in previous studies, with however an average age of DMD diagnosis significantly later than what is usually reported. Our study illustrates the need to implement early molecular diagnosis in order to institute optimal care, including available targeted treatments, for our patients.

**Keywords:** DMD; Dystrophin; Muscular dystrophies; Deletions; Lebanese cohort

Introduction

Duchenne muscular dystrophy (DMD) is a devastating, progressive, X-linked disorder that affects the neuromuscular system in children. It is the most common muscular dystrophy to date, with an incidence of one in 3500–6000 male live births [1,2]. Clinical manifestations are most often absent at birth with normal height and weight [3]. However, the disease evolves quickly with marked muscle weakness and wasting, learning disabilities, loss of ambulation and cardiac complications by the age of 10. Assisted ventilation may become necessary by the age of 20, with death occurring between 20 and 40 years of age [4–6].

DMD is caused by mutations in the dystrophin gene (DMD), which encodes a structural rod-shaped sub-membrane sarcoplasmic protein, which is a major component of a vital protein complex, the dystrophin-associated protein complex (DAPC) [7,8]. Dystrophin is organized into four major domains extending from myofibrillar proteins to sarcolemmal-bound proteins, providing a vital role in force transduction during muscle contraction and a structural role by ensuring the stability of the sarcolemma [9]. Moreover, the multiple domains and binding sites implicate dystrophin in the regulation of different signaling pathways [10]. Dystrophin gene covers more than 2.2 million base pairs and consists of 79 exons [11]. Since its discovery in 1986, thousands of mutations scattered along the whole gene length have been reported [12]. Deletions and duplications of one or more exons constitute the vast majority (70%-80%) of detected genetic aberrations, whereas small rearrangements and point mutations account for the remaining mutations [13]. Sporadic de novo mutations arising either in the mother germ cells or even during the proband’s embryonic development, account for one third of all reported cases [14,15]. In addition to triggering the severe clinicopathological form; Duchenne muscular dystrophy, mutations in the DMD gene are also, at times, responsible for its allelic milder form known as Becker muscular dystrophy (BMD). Most importantly, the disease outcomes are associated, to a certain extent, with the type of the mutation, hence the relevance of early molecular diagnosis [6,16,17]. Moreover, a large number of DMD patients (83%) could theoretically benefit from antisense-mediated exon skipping as most identified deletions cluster to specific hotspots [18].

Detailed information about the nature of DMD associated mutations, their occurrences, and their associated phenotypic patterns will allow appropriate counselling, adequate prognosis, a deeper understanding of the complex genotype-phenotype relationship, an enhanced clinical care, and successful therapeutic trial planning. To our knowledge there is currently no studies performed in Lebanon on the molecular epidemiology of DMD. Here we report the frequency and the distribution pattern of deletions/duplications associated with dystrophin exons as well as the average diagnostic age of DMD in a small Lebanese group of dystrophic patients suspected with DMD/BMD based on clinical features.

*Corresponding author: Dr. Farra Chantal, Department of Pathology and Laboratory Medicine, Medical Genetics Unit, American University of Beirut Medical Center, Beirut, Lebanon, Tel: +961-1-350000 (Ext: 5247); E-mail: chantal.farra@aub.edu.lb

Received September 25, 2018; Accepted October 15, 2018; Published October 18, 2018

Citation: El-Khoury R, Ahdab-Barmada M, Souaid M, Farra C (2018) Molecular Characteristics of Duchenne Muscular Dystrophy in a Lebanese Cohort. J Mol Genet Med 12: 373 doi:10.4172/1747-0862.1000373

Copyright: ©2018 El-Khoury R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Figure 1: Frequencies and patterns of deletions and duplications of DMD gene exons. (A) Exons 6-19 and exons 45-52 represented two deletion hotspots harboring 90% of all single exon deletions and 75% of all deletions combined. (B) Each horizontal bar represents exons deletion/duplication pattern in a single patient.

Figure 2: Schematic representation of the dystrophin gene lined up with its associated multi-domain protein and positioning of deletion hotspots. (A) DMD is made up of 79 exons distributed over 2.2-2.5 Mb. Identified deletion hotspots HS1 and HS2 (red shade) cover exons 6-19 and 45-52 respectively, which particularly impinge on the Rod domain of DMD. The relative distribution of the exons throughout the gene is respected. (B) DMD protein (3685 amino acids) is organized into four distinct domains, 1) The N-terminal actin binding domain (ABD) comprising two calponin homology domains CH1 and CH2, 2) The rod domain, a large central section of 24 structurally similar spectrin-like repeats (R1-R24), interrupted by four proline rich hinges (H1-H4), binds to various partners e.g. rNOS, membrane lipids (LBD), filamentous actin (ABD2), 3) The cysteine rich domain (CRD), which includes two potential EF-hand Ca\(^{2+}\)-binding sites (Efh1-Efh2) that overlap with \(\beta\)-dystroglycan (\(\beta\)-D) and plectin binding sites, a WW domain characterized by the presence of two conserved tryptophan, and a zinc finger (Znf) domain, and 4) The C-terminal domain (CTD) that binds to dystrobrevin and syntrophins. Note that the few examples of DMD partners shown in this figure do not represent an exhaustive list of partners. Data used to construct this figure is from the Leiden Muscular Dystrophy Page (http://www.dmd.nl/) [10,24,25].
Materials and Methods

Patients

Our study included a small group of male patients (n=52) clinically suspected with a Duchenne's type of muscular dystrophy and referred directly to our Medical Genetics Unit for DMD molecular analysis. No prior diagnostic muscle biopsy has been performed on any of the patients. The study was approved by the Institutional Review Board of the American University of Beirut Medical Center. Oral and written consents were provided by the parents and patients to perform and report all needed tests for diagnostic evaluation. Upon their consent, blood was collected from all participants for genetic analysis.

Molecular analysis

Genetic analysis focused mainly on the identification of exon deletions and duplications in the DMD gene by Multiplex Ligation-Dependent Probe Amplification (MLPA) using the SALSA® MLPA® probemixes P034-B2 DMD-1 and P035-B1 DMD-2 from MRC-Holland, Amsterdam-Netherlands. Analysis was carried out according to the manufacturer's instructions. Fluorescent amplification products were visualized by capillary electrophoresis using an automated ABI 3500 genetic analyzer (Applied Biosystems, Foster City, CA). Single exon deletions were further confirmed by PCR and Sanger sequencing. Obtained data were analyzed using the Coffanalyzer. Net, an MLPA analysis software from MRC-Holland.

Results

Patients and molecular genetic findings

A small group of patients who were suspected to express a DMD/BMD pattern of muscular dystrophy on the basis of clinical diagnosis, were included in our investigations. Muscle biopsy and histological studies were not requested and therefore not conducted in neither patient. Genetic analyses were performed in our tertiary care medical genetic unit at the American University of Beirut Medical Center (AUBMC) and aimed mainly at confirming the suspected clinical diagnosis, while further characterizing the frequency and patterns of DMD exons deletions/duplications. Patients were between 3 and 26 years, they were referred from outpatient clinics and were all clinically assessed by referring physicians. All patients were seen for progressive proximal myopathy involving mostly quadriceps, with difficulty climbing stairs and typical Gower's maneuver sign.

Among the 52 cases analyzed molecularly, 35 cases (67%) had positive molecular findings with deletions/duplications covering a big portion of the coding sequence of the dystrophin gene, while 17 cases (33%) were devoid of any detectable large genetic modification (Table 1 and Supplementary Table 1). The vast majority of observed genetic aberrations were deletions (33 cases) with two hot spots identified. The first (HS1) is located N-terminally between exons 6 and 19 while the second (HS2) is located around the middle of the coding sequence between exons 45 and 52 (Figure 1). Both hot spots accounted for 78% of all deletions observed in our group of non-related patients (Figure 2). Deletions starting at HS1 represented 18% of all deletions combined while those starting at HS2 represented 60% of all cases. Single exon deletions were mainly restricted (90%) to identified hotspots, with HS1 harboring 10%, and HS2 80%, of all single exon deletions. Exon 48 was the most commonly deleted exon with an estimated incidence of 6.3%. One deletion spanned over the two hotspots and represented the largest deletion identified in our group of patients. It covered 47 exons that extended from exon 3 to 49. Two cases of duplication were identified in two unrelated patients and involved the same exons (2 to 5). Both duplications were localized outside deletion hotspots. No deletions/duplications were observed C-terminally beyond exon 53. Carrier testing was done in ten females. Six of them were tested because of an affected male sibling, and none of those women was a carrier; and four of them because of an affected male offspring, among which three were found to be carriers. Finally, in our group of male patients, the estimated age average at which the molecular diagnosis was obtained was 7 years (Table 1).

Discussion

The clinical course of Duchenne muscular dystrophy is commonly predictable, and the diagnosis is generally established around three to four years of age [4]. Parents however, often outline a diagnostic endeavor, with diagnosis confirmed more than one to two years from symptoms onset. Early molecular investigations of dystrophin mutations could potentially improve the disease outcomes as different types of mutations carry different phenotypic and prognostic features [6,17].

In the current study we aimed at analyzing the frequency and the distribution pattern of deletions/duplications associated with

| Patient # | Age | Genetic Modification |
|-----------|-----|----------------------|
| P1        | 11  | Del exon 19          |
| P2        | 9   | Del exon 45          |
| P3        | 8   | Del exon 45          |
| P4        | 4   | Del exon 48          |
| P5        | 12  | Del exon 50          |
| P6        | 7   | Del exon 51          |
| P7        | 6   | Del exon 51          |
| P8        | 7   | Del exon 51          |
| P9        | 8   | Del exon 52          |
| P10       | 6   | Del exon 53          |
| P11       | 7   | Del exons 46 to 52   |
| P12       | 6   | Del exons 10 to 19   |
| P13       | 2   | Del exons 10 to 21   |
| P14       | 4   | Del exons 13 to 17   |
| P15       | 7   | Del exons 3 to 11    |
| P16       | 5   | Del exons 3 to 49    |
| P17       | 13  | Del exons 3-4-6-8-12-13 |
| P18       | 7   | Del exons 42 to 54   |
| P19       | 7   | Del exons 42-43      |
| P20       | 9   | Del exons 45 to 49   |
| P21       | 7   | Del exons 45 to 50   |
| P22       | 17  | Del exons 45 to 52   |
| P23       | 6   | Del exons 46 to 48   |
| P24       | 18  | Del exons 46 to 50   |
| P25       | 5   | Del exons 46 to 52   |
| P26       | 9   | Del exons 46 to 52   |
| P27       | 6   | Del exons 47 to 50   |
| P28       | 6   | Del exons 48 to 52   |
| P29       | 4   | Del exons 48 to 53   |
| P30       | 13  | Del exons 5 to 9     |
| P31       | 7   | Del exons 6 to 19    |
| P32       | 3   | Del exons 8 to 41    |
| P33       | 5   | Del exons 46 to 50   |
| P34       | 23  | Dup exons 2 to 5     |
| P35       | 25  | Dup exons 2 to 5     |
dystrophin exons, and the mean diagnostic age of DMD in a small Lebanese group of patients suspected to have an evolving muscular dystrophy with clinical characteristics suggesting a Duchenne’s type. Our data were consistent with previously reported findings with slight differences due mainly to the small number of patients [13,19,20].

Deletions were the most common genetic modification observed in our group of unrelated patients. Among 52 samples analyzed, 33 cases (63%) were identified with deletions of variable sizes ranging from 1 exon to 47 exons. Most deletion events (78%) occurred in two deletion hotspots, HS1 (18%) and HS2 (60%), covering exons 6-19 and 45-52 respectively. Single exon deletions were even further restricted (90%) to the deletion hotspots, mainly to HS2 (80%). A large number of our DMD patients may therefore theoretically benefit from antisense oligonucleotides (AON)-mediated exon skipping, which generate a more stable and partially functional dystrophin protein. Etepliren, a recent FDA approved AON that induces specifically exon 51 skipping, was tested in multiple clinical trials and was shown to slow the disease progression in patients [21]. Although facing many challenges, other AONs targeting additional exons are currently being developed, which will further increase the number of patients that fall in the category adapted to such therapeutic approach [18]. Restoring a reading frame by skipping one or multiple exons is not always of therapeutic significance as some domains represent a docking site for proteins implicated in various essential cellular processes (Figure 2). For instance, R16 and R17 of the rod domain represent the biding site of the neuronal nitric oxide synthase (nNOS), which plays a key role in the regulation of muscle blood flow through NO signaling. R16-R17 segment is encoded by exons 42-45 that are deleted in 24% of our patients, which results in excessive blood flow restriction known as functional ischemia. Combining exon skipping with treatments that boost NO signaling to bypass ischemia, such as Tadalafil (Cialis) and sildenafil (Viagra, Revatio) could represent the optimal approach in those cases.

In addition to deletions, two cases (4%) with duplications affecting exons 2-5 were identified. No large genetic aberrations were observed beyond exon 53. Such result does not exclude the occurrence of deletions/duplications in the C-terminal domain of the dystrophin gene; rather it potentially reflects the small group size and the low frequency of deletions observed worldwide in that particular domain. Furthermore, 17 cases (33%) were devoid of large genetic modifications as indicated by MLPA analysis. Those represent most likely cases of small insertions/deletions and point mutations or may represent cases that fall within a different group of muscular dystrophies harboring similar features to that observed in DMD/DMB such as Limb girdle muscular dystrophies and Emery-Dreifuss muscular dystrophies.

The estimated age average at which the molecular diagnosis was obtained in our group of patients was 7 years compared to 4-5 years worldwide [22]. Our data are presumably indicative of a lack of awareness of the disease by both parents, mostly coming from rural areas with low socioeconomic background, and the primary care physicians. This highlights the pressing need for an educative scheme by care facilities to enhance early diagnosis. Muscle quality was also shown to be an essential feature for successful therapeutic interventions aiming at restoring DMD expression [8]. Indeed, development of fibrosis and fat accumulation in DMD patients’ skeletal muscles are early and progressive events that will impede treatment efficiencies. Enhancing early molecular diagnosis is therefore critical for an optimal outcome of the disease as it will allow appropriate counseling, and eventual targeted care and follow up.

Our data also laid stress on the relevance of a muscle biopsy for the evaluation, diagnosis and treatment of DMD patients. Histochemical and immunohistochemical analyses allow a comprehensive characterization of the impact of DMD mutations on the structure and function of skeletal muscles. Such impact can be highly variable, and mainly linked to the existence of genetic modifiers [23-25]. Investigations which would include a muscle biopsy, in parallel to molecular analysis, provide compelling evidence that allow differential diagnosis, optimization of therapeutic management, and establishment of appropriate preventive care.

Conclusion
The information obtained from the current work will represent an incentive, for us and others, to initiate additional exhaustive studies, including larger groups of dystrophic patients from our society. Such studies will allow the establishment of a comprehensive national database, which will be extremely beneficial for basic research, trial development, and clinical care.

Acknowledgment
This study is supported by the Medical Genetics Unit and Neuromuscular Diagnostic Laboratory of the Pathology and Laboratory Medicine Department at AUBMC.

References
1. Emery AE (1991) Population frequencies of inherited neuromuscular diseases: A world survey. Neuromuscul Disorders 1: 19–29.
2. Mendell JR, Shilling C, Leslie ND, Flanagan KM, Al-Dahkhah R, et al. (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71: 304–313.
3. Sarazin E, Von Der Hagen M, Schara U (2014) Growth and psychomotor development of patients with Duchenne muscular dystrophy. Eur J Paediatr Neurol 18: 38–44.
4. Brooke MH, Fenichel GM, Griggs RC (1989) Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy. Neurology 39: 475-481.
5. Eagle M, Boudouin SV, Chandler C (2002) Survival in Duchenne muscular dystrophy: Improvements in life expectancy since 1987 and the impact of home nocturnal ventilation. Neuromuscular Disorders 12: 926–929.
6. Amario D, Amodeo A, Adoriso R (2017) A current approach to heart failure in Duchenne muscular dystrophy. Heart 103: 1770–1779.
7. Erevst JM, Campbell KP (1991) Membrane organization of the dystrophin-glycoprotein complex. Cell 66: 1121–1131.
8. Guiraud S, Aartsma-Rus A, Vieira NM (2015) The pathogenesis and therapy of muscular dystrophies. Ann Rev Genom Human Genet 16: 281–308.
9. Constantin B (2014) Dystrophin complex functions as a scaffold for signaling proteins. Biochimica et Biophysica Acta (BBA)-Biombrenes 1838: 635–642.
10. Allen DG, Whitehead NP, Froehner SC (2016) Absence of dystrophin disrupts skeletal muscle signalling: Roles of Ca++, reactive oxygen species, and nitric oxide in the development of muscular dystrophy. Physiol Rev 96: 253–305.
11. Van Ommen GJ, Bertelson C, Ginjar HB (1987) Long-range genomic map of the Duchenne muscular dystrophy (DMD) gene: Isolation and use of J66 (DXS268), a distal intragenic marker. Genomics 1: 329–336.
12. Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51: 919–928.
13. Tuffery-Giraud S, Béroud C, Léturcq F (2009) Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: A model of nationwide knowledgebase. Hum Mutat 30: 934–945.
14. Bakker E, Van Broeckhoven C, Bonten EJ (2017) Germline mosaicism and Duchenne muscular dystrophy mutations. Nature 329: 554–556.
15. Van Essen AJ, Mulder IM, Van Der Vlies P (2003) Detection of point mutation in dystrophin gene reveals somatic and germline mosaicism in the mother of a patient with Duchenne muscular dystrophy. Am J Med Genet A 118A: 296–298.
16. Moizard MP, Billard C, Toutain A (1998) Are Dp71 and Dp140 brain dystrophin isoforms related to cognitive impairment in Duchenne muscular dystrophy?. Am J Med Genet 80: 32–41.

17. Felisari G, Martinelli Boneschi F, Bardoni A (2000) Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy. Neurology 55: 559–564.

18. Aartsma-Rus A, Ferlini A, Goemans N (2014) Translational and regulatory challenges for exon skipping therapies. Hum Gene Ther 25: 885–892.

19. Aartsma-Rus A, Van Deutekom JCT, Fokkema IF (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34: 135–144.

20. Ma P, Zhang S, Zhang H (2018) Comprehensive genetic characteristics of dystrophinopathies in China. Orphanet J Rare Dis 13: 109.

21. Aartsma-Rus A, Krieg AM (2017) FDA approves eteplirsen for Duchenne muscular dystrophy: The next chapter in the eteplirsen saga. Nucleic Acid Ther 27: 1–3.

22. Ciafaloni E, Fox DJ, Pandya S (2009) Delayed diagnosis in Duchenne muscular dystrophy. Data from the muscular dystrophy surveillance, tracking, and research network (MD STARnet). J Pediatr 155: 380–385.

23. Flanigan KM (2014) Duchenne and Becker muscular dystrophies. Neurol Clin 32: 671–688.

24. Norwood FL, Sutherland-Smith AJ, Keep NH, Kendrick-Jones J (2000) The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. Structure 8: 481–491.

25. Nicolas A, Lucchetti-Miganeh C, Yaou RB (2012) Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the e-Dystrophin online database. Orphanet Journal of Rare Diseases 7: 45.